Novel prodrug of simvastatin as cascade latentiated inhibitor of HMG-COA reductase

Asian Journal of Pharmaceutical and Clinical Research

Volumn 5, Issue SUPPL.1, 2012, Pages 50-52

  Gupta, Arun K ^a   Joshi, Megha ^a   Sabarwal, Neetu ^a   Agrawal, Yogesh P ^a   Jain, Sanjay ^a  

^a Smriti College of Pharmaceutical Education   (India)

Author keywords

Hypercholesterolemia; Oxime; Prodrugs; Simvastatin

Indexed keywords

NITROGEN OXIDE; OXIME DERIVATIVE; PRODRUG; SIMVASTATIN;

ARTICLE; CONTROLLED STUDY; DRUG FORMULATION; DRUG HYDROLYSIS; DRUG SOLUBILITY; DRUG STRUCTURE; HYDROPHILICITY; IN VITRO STUDY; INFRARED SPECTROSCOPY; MASS SPECTROMETRY; MELTING POINT; PH MEASUREMENT; PROTON NUCLEAR MAGNETIC RESONANCE; THIN LAYER CHROMATOGRAPHY;

EID: 84863415636     PISSN: 09742441     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Brunton, L.L.; Lazo, S.J.; Parkers, L.K. The pharmacological basis of therapeutics, 2006, 11th edition, 948-953.
2. Williams, A. D.; Lemke L. T. Foye's Principle of medicinal chemistry, 2002, 5th edition, 588-594.
3. Laws, P. E. Eur. J. Vas. Endovas. Sur., 2004, 27, 6-16.
4. Schachter, M. Fundament. Clin. Pharmacol., 2004, 19, 1,117-125.
5. Rao, H.S.P. Resonance, Feb., 2003, 7, 19-27.
6. Stella V.J. Prodrugs: Challenges and rewards. Part 1. Department of Pharmaceutical Chemistry the University of Kansas, Lawrence, Kansas, 66047 USA.
7. Kumpulainen, H. Ph.D. Thesis. Kuopio university publications A. Pharmaceutical sciences, 2007, 104.
8. Testa, B. Prodrug research: futile or fertile? Biochem. Pharmacol. 2004, 68, 2097-2106.
9. Verma A., Verma B., Prajapati S. K., Tripathi K. Prodrug as a chemical delivery system Asian J. Res. Chem., 2009, 2, 100-103.
10. Ettmayer P., Gordon L. A., Bernd C., and Testa B. Lessons Learned from Marketed and Investigational Prodrugs; J. Med. Chem., 2004, 47, 2393-2404.
11. Stella, V.J.; Nti-Addae, W.K. Prodrug strategies to overcome poor water solubility; Adv. Drug Del. Rev., 2007, 59, 677-694.
12. Fleisher, D. Bong R., Stewart B. H., Improved oral drug delivery: solubility limitations overcome by the use of Prodrug; Adv. Drug Del. Rev., 1996, 19, 115-130.
13. Majumdar, S.; Duvvuri, S.; Mitra, A.K., Membrane transporter/receptor-targeted Prodrug design: strategies for human and veterinary drug development. Adv. Drug Del. Rev., 2004, 56, 1437-1452.
14. Martin D'Souza, Venkataramanan R., D'Mello A., Niphadkar P., An alternative prodrug approach for reducing presystemic metabolism of drugs. Int. J. Pharma., 1986, 31,165-167.
15. Hyo K.H., Gordon L.A., Targeted Prodrug Design to Optimize Drug Deliver. AAPS Pharm. Sci., 2000, 2 (1), 1-11.
16. Igarashi, R.; Mizushima, Y.; Takenega, M.; Matsumoto, K.; Morizawa, Y.; Yasuda A., A stable PGE1 Prodrug for targeting therapy. J. Cont. Rel., 1992, 20, 37-46.
17. Guang, Xu., McLeo H. L., Strategies for Enzyme/Prodrug Cancer Therapy. Clin. Cancer Res. 2001; 7:3314-3324.
18. Bundgaard H., The double Prodrug concept and its applications. Adv. Drug Del. Rev., 1989, 3, 39-65.
19. Seoung, W. J., Min-Soo K., Jeong-Soo K., Park H. J., Lee S., Jong-Soo W., Sung-Joo H., Preparation and characterization of simvastatin/hydroxypropyl-β-cyclodextrin inclusion complex using supercritical anti-solvent (SAS) process. Eur. J. Pharm. Biopharm., 2007, 66, 413-421.
20. Dsilva T., Jackson A.L., Valquiria T.A., Nivaldo L.S., Christina D.V.S., II-Latin-American symposium on polymorphism and crystallization in drugs and Medicines, March 2009, Estancio de Sao Pedro, Brazil.
21. Mantyla A., Rautio J., Nevalainen T., Juvonen R., Kendrick H., Garnier T., Croft S.L., Jearvinen T., Jouko V., Synthesis and antileishmanial activity of novel buparvaquone oxime derivatives. Bioorg. Med. Chem., 2004, 12, 3497-3502.
22. Mantyla A., Rautio J., Nevalainen T., Juvonen R., Pekka K. R., Jearvinen T., Jouko V., Design, synthesis and in vitro evaluation of novel water-soluble prodrugs of buparvaquone. Eur J. Pharm. Sci., 2004, 23, 151-158.